QNRX
Income statement / Annual
Last year (2025), Quoin Pharmaceuticals Ltd's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Quoin Pharmaceuticals Ltd's net income was -$15.80 B.
See Quoin Pharmaceuticals Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$280.00 K |
$0.00 |
-$280.00 K |
| Cost of Revenue |
$100.79 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$227.06 K
|
$125.72 K
|
$104.22 K
|
$89.13 K
|
| Gross Profit |
-$100.79 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$227.06 K
|
-$405.72 K
|
-$104.22 K
|
-$369.13 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1.45
|
0
|
1.32
|
| Research and Development Expenses |
$9.80 B
|
$3.60 M
|
$3.31 M
|
$2.67 M
|
$1.56 M
|
$244.16 K
|
$45.65 K
|
$8.26 M
|
$5.89 M
|
$8.26 M
|
| General & Administrative Expenses |
$6.49 B
|
$5.93 M
|
$6.07 M
|
$6.58 M
|
$4.50 M
|
$1.43 M
|
$1.51 M
|
$7.97 M
|
$4.20 M
|
$7.97 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.49 B
|
$5.93 M
|
$6.07 M
|
$6.58 M
|
$4.50 M
|
$1.43 M
|
$1.51 M
|
$7.97 M
|
$4.20 M
|
$7.97 M
|
| Other Expenses |
-$16.27 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$16.32 M
|
$9.53 M
|
$9.38 M
|
$9.26 M
|
$6.06 M
|
$1.67 M
|
$1.56 M
|
$16.22 M
|
$10.10 M
|
$16.22 M
|
| Cost And Expenses |
$16.42 M
|
$9.53 M
|
$9.38 M
|
$9.26 M
|
$6.06 M
|
$1.67 M
|
$1.56 M
|
$16.22 M
|
$10.10 M
|
$16.22 M
|
| Interest Income |
$485.91 K
|
$558.49 K
|
$694.61 K
|
$95.75 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$714.08 K
|
$1.09 M
|
$1.19 M
|
$412.29 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$100.79 K
|
$100.00 K
|
$103.71 K
|
$104.04 K
|
$104.04 K
|
$104.04 K
|
$227.06 K
|
$125.72 K
|
$104.22 K
|
$89.13 K
|
| EBITDA |
-$16.32 M |
-$9.43 M |
-$9.27 M |
-$8.56 M |
-$20.27 M |
-$1.57 M |
-$1.54 M |
-$5.47 M |
-$7.80 M |
-$3.91 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
19.53
|
0
|
13.95
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-54.7
|
0
|
-54.7
|
| Total Other Income/Expenses Net |
$489.30 K
|
$565.99 K
|
$691.93 K
|
-$123.79 K
|
-$15.40 M
|
-$425.35 K
|
$0.00
|
$2.54 M
|
-$1.06 M
|
$237.07 K
|
| Income Before Tax |
-$15.93 M
|
-$8.96 M
|
-$8.69 M
|
-$9.38 M
|
-$21.46 M
|
-$2.10 M
|
-$1.56 M
|
$15.32 M
|
$10.17 M
|
$15.32 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-54.7
|
0
|
-54.7
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$161.14 K
|
-$1.17 M
|
$147.94 K
|
| Net Income |
-$15.80 B
|
-$8.96 M
|
-$8.69 M
|
-$9.38 M
|
-$21.46 M
|
-$2.10 M
|
-$1.56 M
|
$15.32 M
|
$10.17 M
|
$15.32 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-54.7
|
0
|
-54.7
|
| EPS |
-14796.26 |
-66.85 |
-337.47 |
-22.97 |
-28543.2 |
-88.1 |
-440.29 |
7100.73 |
5450.81 |
10084 |
| EPS Diluted |
-14796.26 |
-66.85 |
-337.47 |
-22.97 |
-28543.2 |
-88.1 |
-440.29 |
7100.73 |
5450.81 |
10084 |
| Weighted Average Shares Out |
$1.07 M
|
$133.96 K
|
$25.74 K
|
$403.88 K
|
$1.60 K
|
$20.02 K
|
$3.54 K
|
$2.16 K
|
$1.87 K
|
$1.52 K
|
| Weighted Average Shares Out Diluted |
$1.07 M
|
$133.96 K
|
$25.74 K
|
$403.88 K
|
$1.60 K
|
$20.02 K
|
$3.54 K
|
$2.16 K
|
$1.87 K
|
$1.52 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
